Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine

References

• Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287–333
   PubMed Web of Science ®Google Scholar
• Smith BH, Elliott AM, Chambers WA, et al. The impact of chronic pain in the community. Fam Pract 2001;18:292-9
   PubMed Web of Science ®Google Scholar
• Sprangers MA, de Regt EB, Andries F, et al. Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol 2000;53:895-907
   PubMed Web of Science ®Google Scholar
• Crichton B, Green M. GP and patient perspectives on treatment with non-steroidal anti-inflammatory drugs for the treatment of pain in osteoarthritis. Curr Med Res Opin 2002;18:92-6
   PubMed Web of Science ®Google Scholar
• Doth AH, Hansson PT, Jensen MP, et al. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain 2010;149:338-44
   PubMed Web of Science ®Google Scholar
• Zelman DC, Dukes E, Brandenburg N, et al. Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain 2005;115:29-36
   PubMed Web of Science ®Google Scholar
• Nuesch E, Dieppe P, Reichenbach S, et al. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 2011;342:d1165
   PubMed Web of Science ®Google Scholar
• Torrance N, Elliott AM, Lee AJ, et al. Severe chronic pain is associated with increased 10 year mortality. A cohort record linkage study. Eur J Pain 2010;14:380-6
   PubMed Web of Science ®Google Scholar
• Phillips C. Economic burden of chronic pain. Expert Rev Pharmacoecon Outcomes Res 2006;6:591-601
   PubMedGoogle Scholar
• Katz WA, Barkin RL. Dilemmas in chronic/persistent pain management. Am J Ther 2008;15:256-64
   PubMed Web of Science ®Google Scholar
• Moore RA, Straube S, Paine J, et al. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149:360-4
   PubMedGoogle Scholar
• Straube S, Moore RA, Paine J, et al. Interference with work in fibromyalgia - effect of treatment with pregabalin and relation to pain response. BMC Musculoskelet Disord 2011;12:125
   PubMed Web of Science ®Google Scholar
• Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372-80
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Lindsey CD. How effective is long-term opioid therapy for chronic noncancer pain? Clin J Pain 2007;23:300-2
   PubMed Web of Science ®Google Scholar
• Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008;11(2 Suppl):S5-S62
   PubMed Web of Science ®Google Scholar
• Collet B-J. Chronic opioid therapy for non-cancer pain. Br J Anaesth 2001;87:133-43
   PubMed Web of Science ®Google Scholar
• Snidvongs S, Mehta V. Recent advances in opioid prescription for chronic non-cancer pain. Postgrad Med J 2012;88:66-72
   PubMedGoogle Scholar
• Moore RA, Eccleston C, Derry S, et al. ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief; Cochrane pain, palliative and supportive care systematic review group editors. “Evidence” in chronic pain–establishing best practice in the reporting of systematic reviews. Pain 2010;150:386-9
   PubMed Web of Science ®Google Scholar
• McDermott AM, Toelle TR, Rowbotham DJ, et al. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006;10:127-35
   PubMed Web of Science ®Google Scholar
• Eriksen J, Sjogren P, Bruera E, et al. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 2006;125:172-9
   PubMed Web of Science ®Google Scholar
• OPEN Minds. The white paper on opioids and pain: a pan-European challenge. 2005. http://www.dgss.org/fileadmin/pdf/50616_White_Paper.pdf. Accessed December 21, 2011
   Google Scholar
• Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003;63:17-32
   PubMed Web of Science ®Google Scholar
• Nicholson B, Passik SD. Management of chronic non-cancer pain in the primary care setting. South Med J 2007;100:1028-36
   PubMed Web of Science ®Google Scholar
• Moore RA, Straube S, Derry S, et al. Chronic low back pain analgesic studies -- a methodological minefield. Pain 2010;149:431-4
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol HCI. Drugs Future 2006;31:1053-61
   Web of Science ®Google Scholar
• Tzschentke TM, Christoph T, Kogel B, et al. (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323:265-76
   PubMed Web of Science ®Google Scholar
• Upmalis D, Okamoto A, Van Hove I, et al. Efficacy and tolerability data supporting the use of tapentadol immediate release for the relief of pain from end-stage joing disease [abstract]. Paris: 9th Annual European Congress of Rheumatology (EULAR 2008), 2008
   Google Scholar
• Oh C, Upmalis D, Okamoto A, et al. Flexible use of tapentadol immediate release for 90 days for the treatment of low back pain and osteoarthritis pain: a safety study [abstract]. Paris: 9th Annual European Congress of Rheumatology (EULAR 2008), 2008
   Google Scholar
• Hartrick C, Van Hove I, Stegmann JU, et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 2009;31:260-71
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Jahnel U, Kogel B, et al. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today (Barc) 2009;45:483-96
   PubMed Web of Science ®Google Scholar
• Afilalo M, Etropolski M, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled Phase III study. Clin Drug Investig 2010;30:489-505
   PubMed Web of Science ®Google Scholar
• Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother 2010;11:1787-804
   PubMed Web of Science ®Google Scholar
• Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010;27:381-99
   PubMed Web of Science ®Google Scholar
• Obradovic M, Baxter G, Conway P, et al. Cost effectiveness of tapentadol PR compared with oxycodone CR for the treatment of severe chronic pain. Poster presented at the British Pain Society and Canadian Pain Society Joint Annual Scientific Meeting. 21–24th June 2011, Edinburgh, Scotland
   Google Scholar
• Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144-54
   PubMed Web of Science ®Google Scholar
• Milligan K, Lanteri-Minet M, Borchert K, et al. Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain 2001;2:197-204
   PubMed Web of Science ®Google Scholar
• Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther 2006;28:943-52
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium (eMC). Summary of Product Characteristics of OxyContin tablets. 2011. http://www.emc.medicines.org.uk/medicine/2579/SPC/OxyContin%20tablets/#POSOLOGY. Accessed December 8, 2011
   Google Scholar
• Donner B, Zenz M, Tryba M, et al. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996;64:527-34
   PubMed Web of Science ®Google Scholar
• NHS England. Prescribing Support Unit. 2011, Health and Social Care Information Centre, prescription cost analysis England, 2010. http://www.ic.nhs.uk/webfiles/publications/007_Primary_Care/Prescribing/Prescription_Cost_Analysis_England_2010/Prescription_Cost_Analysis_2010.pdf. Accessed December 21, 2011
   Google Scholar
• Gross Domestic Product (GDP) deflators. HM Treasury. http://www.hm-treasury.gov.uk/data_gdp_index.htm. Accessed March 1, 2011
   Google Scholar
• Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010;10:416-27
   PubMed Web of Science ®Google Scholar
• Bachmeier CJ, March LM, Cross MJ, et al. Arthritis Cost and Outcome Project Group. A comparison of outcomes in osteoarthritis patients undergoing total hip and knee replacement surgery. Osteoarthritis Cartilage 2001;9:137-46
   PubMed Web of Science ®Google Scholar
• Summers KH, Amy Puenpatom R, Rajan N, et al. Economic impact of potential drug-drug interactions in opioid analgesics. J Med Econ 2011;14:390-6.
   PubMedGoogle Scholar
• Langley P, Müller-Schwefe G, Nicolaou A, et al. The impact of pain on labor force participation, absenteeism and presenteeism in the European Union. J Med Econ 2010;13:662-72
   PubMedGoogle Scholar